A Case for Phosphoinositide 3-Kinase–Targeted Therapy for Infectious Disease

Inhibition of PI3Kδ Enhances Poly I:C-Induced Antiviral Responses and Inhibits Replication of Human Metapneumovirus in Murine Lungs and Human Bronchial Epithelial Cells

(2020) Akitaka Fujita et al.   Frontiers in Immunology

Targeting PI3K in cancer: mechanisms and advances in clinical trials

(2019) Jing Yang et al.   Molecular Cancer

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function

(2019) Stalin Chellappa et al.   JOURNAL OF IMMUNOLOGY

Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase δ

(2019) David J Swan et al.   HAEMATOLOGICA

PI 3K δ is a Treg target in cancer immunotherapy

(2019) Ee Lyn Lim et al.   IMMUNOLOGY

Active PI3K abrogates central tolerance in high-avidity autoreactive B cells

(2019) Sarah A. Greaves et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Precision B Cell–Targeted Therapeutic Approach to Autoimmunity Caused by Phosphatidylinositol 3-Kinase Pathway Dysregulation

(2019) S. Elizabeth Franks et al.   JOURNAL OF IMMUNOLOGY

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

T and B‐cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity

(2019) Silvia Preite et al.   IMMUNOLOGICAL REVIEWS

Efficacy of PI3K inhibitors in advanced breast cancer

(2019) B Verret et al.   ANNALS OF ONCOLOGY

Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology

(2019) Andrew J. Takeda et al.   Nature Communications

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

(2019) Martin Dreyling et al.   AMERICAN JOURNAL OF HEMATOLOGY

PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy

(2018) Flora Pirozzi et al.   CURRENT MEDICINAL CHEMISTRY

Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity

(2018) Emily S.J. Edwards et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Primary immunodeficiency disorder caused by phosphoinositide 3-kinase delta (PI3Kδ) deficiency

(2018) Georgios Sogkas et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication

(2018) Grant R. Campbell et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Germline-activating mutations inPIK3CDcompromise B cell development and function

(2018) Danielle T. Avery et al.   JOURNAL OF EXPERIMENTAL MEDICINE

TAPP Adaptors Control B Cell Metabolism by Modulating the Phosphatidylinositol 3-Kinase Signaling Pathway: A Novel Regulatory Circuit Preventing Autoimmunity

(2018) Nipun Jayachandran et al.   JOURNAL OF IMMUNOLOGY

Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration

(2018) Ahmed Y. Ali et al.   LEUKEMIA

Role of Bruton’s tyrosine kinase in B cells and malignancies

(2018) Simar Pal Singh et al.   Molecular Cancer

PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer

(2018) Qiang Wang et al.   Cell Death & Disease

Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome

(2018) Alison M. Condliffe et al.   Frontiers in Immunology

Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome

(2018) Takaki Asano et al.   Frontiers in Immunology

Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

(2018) Ryan J. Sullivan et al.   JOURNAL OF CLINICAL ONCOLOGY

Activated PIK3CD drives innate B cell expansion yet limits B cell–intrinsic immune responses

(2018) Michelle N. Wray-Dutra et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Hyperactivated PI3Kδ promotes self and commensal reactivity at the expense of optimal humoral immunity

(2018) Silvia Preite et al.   NATURE IMMUNOLOGY

PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner

(2018) Anne-Katrien Stark et al.   Nature Communications

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

(2018) Günter Krause et al.   Drug Design Development and Therapy

Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8+ T Cell Survival, Differentiation, and Function

(2018) Jennifer L. Cannons et al.   Frontiers in Immunology

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

(2018) Ian W. Flinn et al.   BLOOD

Activated Phosphoinositide 3 Kinase Delta Syndrome (APDS)

(2018) Frederic Baleydier et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Marek’s Disease Virus Activates the PI3K/Akt Pathway Through Interaction of Its Protein Meq With the P85 Subunit of PI3K to Promote Viral Replication

(2018) Huimin Li et al.   Frontiers in Microbiology

Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia

(2017) Hima V. Vangapandu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Novel PIK3CD mutations affecting N-terminal residues of p110δ cause activated PI3Kδ syndrome (APDS) in humans

(2017) Andrew J. Takeda et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study

(2017) Tanya I. Coulter et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization

(2017) Eleni Vergadi et al.   JOURNAL OF IMMUNOLOGY

Innate Control of Adaptive Immunity: Beyond the Three-Signal Paradigm

(2017) Aakanksha Jain et al.   JOURNAL OF IMMUNOLOGY

Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD

(2017) A. Cahn et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells

(2017) Jacob S. Bowers et al.   Frontiers in Immunology

Emerging evidence of signalling roles for PI(3,4)P2 in Class I and II PI3K-regulated pathways

(2016) P. T. Hawkins et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study

(2016) Elodie Elkaim et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis

(2016) Forough Khadem et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+T Cell Responses during Acute Viral and Intracellular Bacterial Infections

(2016) Donald T. Gracias et al.   JOURNAL OF IMMUNOLOGY

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

PI3K/Akt promotes feedforward mTORC2 activation through IKKα

(2016) Han C. Dan et al.   Oncotarget

PI3K signalling in inflammation

(2015) P.T. Hawkins et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: A distinct branch of PI3K signaling

(2015) Hongzhao Li et al.   CELLULAR SIGNALLING

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

(2015) S. Rafii et al.   CLINICAL CANCER RESEARCH

PI3K inhibitors in inflammation, autoimmunity and cancer

(2015) Anne-Katrien Stark et al.   CURRENT OPINION IN PHARMACOLOGY

Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration

(2015) Michiko Horiguchi et al.   JOURNAL OF CONTROLLED RELEASE

PI3Kδ Regulates the Magnitude of CD8+T Cell Responses after Challenge withListeria monocytogenes

(2015) Verity Q. Pearce et al.   JOURNAL OF IMMUNOLOGY

PI3K/AKT signaling pathway and cancer: an updated review

(2014) Miriam Martini et al.   ANNALS OF MEDICINE

Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis

(2014) Jason Kindrachuk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Inhibition of PI3Kδ Improves Systemic Lupus in Mice

(2014) Yanxia Wang et al.   INFLAMMATION

Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling

(2014) Craig M. Walsh et al.   JOURNAL OF CLINICAL INVESTIGATION

Genetic Analysis of the Role of the PI3K-Akt Pathway in Lipopolysaccharide-Induced Cytokine and Tissue Factor Gene Expression in Monocytes/Macrophages

(2014) J. P. Luyendyk et al.   JOURNAL OF IMMUNOLOGY

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers

(2014) David A. Fruman et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity

(2013) Klaus Okkenhaug   Annals of the New York Academy of Sciences

Phosphatidylinositol-3,4,5-trisphosphate: Tool of choice for class I PI 3-kinases

(2013) Rachel Schnur Salamon et al.   BIOESSAYS

Regulatory functions of innate-like B cells

(2013) Xiaoming Zhang   Cellular & Molecular Immunology

PI3Kγ kinase activity is required for optimal T-cell activation and differentiation

(2013) Nadia Ladygina et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency

(2013) Carrie L Lucas et al.   NATURE IMMUNOLOGY

Toxoplasma gondii Proliferation Require Down-Regulation of Host Nox4 Expression via Activation of PI3 Kinase/Akt Signaling Pathway

(2013) Wei Zhou et al.   PLoS One

Phosphoinositide 3-Kinase   Gene Mutation Predisposes to Respiratory Infection and Airway Damage

(2013) I. Angulo et al.   SCIENCE

Toll-like receptors, signaling adapters and regulation of the pro-inflammatory response by PI3K

(2012) Ty Dale Troutman et al.   CELL CYCLE

Inhibition of Mycobacterial Infection by the Tumor Suppressor PTEN

(2012) Guochang Huang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PI3K signalling: the path to discovery and understanding

(2012) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies

(2012) Kamal D. Puri et al.   Frontiers in Immunology

The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions

(2012) Samantha D. Pauls et al.   Frontiers in Immunology

Immunotherapy with PI3K Inhibitor and Toll-Like Receptor Agonist Induces IFN- +IL-17+ Polyfunctional T Cells That Mediate Rejection of Murine Tumors

(2011) N. A. Marshall et al.   CANCER RESEARCH

Evidence for Direct Activation of mTORC2 Kinase Activity by Phosphatidylinositol 3,4,5-Trisphosphate

(2011) Xiaoqing Gan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PI3K signalling in lymphocyte migration

(2010) Aurore Saudemont et al.   CELL CYCLE

FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages

(2010) WuQiang Fan et al.   EMBO JOURNAL

Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ

(2010) Jennifer K. Uno et al.   GASTROENTEROLOGY

CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients

(2010) Paul A. Blair et al.   IMMUNITY

The p110  Isoform of Phosphatidylinositol 3-Kinase Controls the Quality of Secondary Anti-Leishmania Immunity by Regulating Expansion and Effector Function of Memory T Cell Subsets

(2010) D. Liu et al.   JOURNAL OF IMMUNOLOGY

Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction

(2010) J. Rolf et al.   JOURNAL OF IMMUNOLOGY

The Kinase Akt1 Controls Macrophage Response to Lipopolysaccharide by Regulating MicroRNAs

(2009) Ariadne Androulidaki et al.   IMMUNITY

Suppression of Phosphatidylinositol 3,4,5-Trisphosphate Production Is a Key Determinant of B Cell Anergy

(2009) Cecille D. Browne et al.   IMMUNITY

Phosphoinositide 3-kinase-regulated adapters in lymphocyte activation

(2009) Ting-ting Zhang et al.   IMMUNOLOGICAL REVIEWS

The p110  Isoform of Phosphatidylinositol 3-Kinase Controls Susceptibility to Leishmania major by Regulating Expansion and Tissue Homing of Regulatory T Cells

(2009) D. Liu et al.   JOURNAL OF IMMUNOLOGY

Role of phosphoinositide 3-kinase p110δ in TLR4- and TLR9-mediated B cell cytokine production and differentiation

(2009) Nyla Dil et al.   MOLECULAR IMMUNOLOGY

Effective clearance of intracellularLeishmania majorin vivo requires Pten in macrophages

(2008) Shoko Kuroda et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages

(2008) E. A. Papakonstanti et al.   JOURNAL OF CELL SCIENCE

Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy

(2008) Pauline Chugh et al.   Retrovirology